Exercise may counteract side effects of prostate cancer hormone therapy
NCT ID NCT07680920
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial investigates whether a supervised program of aerobic and strength training can improve quality of life, heart function, and body composition in men with prostate cancer who are receiving androgen deprivation therapy (hormone therapy). The study involves 46 men aged 40 to 75 with stage I-III prostate cancer. Participants will be randomly assigned to either a 12-week supervised exercise group or a control group. Researchers will measure changes in quality of life, physical function, blood pressure, and body fat before and after the program.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- supervised combined aerobic and strength training
- What this could lead to
- If effective, supervised exercise could become a standard way to reduce side effects of hormone therapy for prostate cancer, improving daily life and heart health.
- What could go wrong
- This is a small, early-stage trial with only 46 participants, so results may not apply to all patients. Exercise may not significantly improve all measured outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 46 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 75 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Clinical diagnosis of prostate cancer stages I-III; Currently undergoing androgen deprivation therapy (ADT); Aged 40 to 75 years; No participation in research involving physical exercise or any systematic physical exercise intervention during the four months preceding the intervention; Residence in the Greater Florianópolis region, Santa Catarina, Brazil; Provision of written informed consent. Exclusion Criteria: Current participation in a structured physical exercise program; Presence of musculoskeletal disorders or other diseases that may prevent participation in the intervention or the assessment procedures.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Androgen deprivation therapy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test outsmart prostate cancer?
- Can a single radiation type spare prostate cancer patients from extra side effects?
- Can a Triple-Drug cocktail before surgery curb prostate Cancer's return?
- AI chatbot aims to demystify prostate cancer radiation — a trial puts it to the test
- Combination therapy aims to wipe out High-Risk prostate cancer before surgery
- Can a digital guide boost genetic testing in prostate cancer survivors?